Rudolf M. T. De Wildt,Steve Holmes,Ian M. Tomlinson,Gregory P. Winter,Mary F. Fitzgerald,Justian Craig Fox,Armin Sepp,Jennifer Luckett,Benjamin P. Woolven
申请号：
US15469839
公开号：
US20170210814A1
申请日:
2017.03.27
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed arc the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.
